Updates on audited Financial Result for September 30, 2016
Suven Life Sciences Ltd has informed BSE that the company will release Ind-AS compliant un-audited financial results for the quarter/ half-year ended September 30, 2016 within the extended time lines as permitted by SEBI vide circular dated July 05, 2016. Notice of Board Meeting will be issued by the company at appropriate time. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Suven Life Sciences Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Suven Life gets patents in Europe, Israel for neuro-degenerative drug candidate
Products out of the inventions may be out-licenced at various phases of clinical development like phase-I or phase-II, Suven says Suven Life Sciences secures two (2) Product Patents in Europe and Israel
Suven Life Sciences Ltd has informed BSE regarding a Press Release dated October 18, 2016 titled "Suven Life Sciences secures two (2) Product Patents in Europe and Israel". Shareholding for the Period Ended September 30, 2016
Suven Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here Suven Life secures patents for CNS drug in India and Japan
These patents are valid through 2026 and 2032 in India and Japan, respectively Suven gets 2 product patents for CNS molecules
Suven Life Sciences has been granted two product patents, one each in India and Japan, for the molecules to be developed for the treatment of neuro-degenerative diseases.The company has been granted Suven Life Sciences secures two (2) Product Patents in India and Japan
Suven Life Sciences Ltd has informed BSE regarding a Press Release dated September 26, 2016 titled "Suven Life Sciences secures two (2) Product Patents in India and Japan". Suven gets product patent for neuro-degenerative drug
Suven Life Sciences has been granted a patent each by Canada, Europe and Hong Kong for a drug used in the treatment of neuro-degenerative diseases. In a BSE filing today, Suven Life said: The gran... Suven Life Sciences secures three (3) Product Patents in Canada, Europe and Hong Kong
Suven Life Sciences Ltd has informed BSE regarding a Press Release dated September 08, 2016, titled "Suven Life Sciences secures three (3) Product Patents in Canada, Europe and Hong Kong".